Previous 10 | Next 10 |
BRIDGEWATER, N.J., April 13, 2023 (GLOBE NEWSWIRE) -- Hillstream BioPharma, Inc. (Nasdaq: HILS) ("Hillstream" or the "Company"), a biotechnology company developing therapeutic candidates targeting drug resistant and devastating cancers using ferroptosis, an emerging new anti-cancer mechanism resu...
BRIDGEWATER, NJ / ACCESSWIRE / April 12, 2023 / A surge in oncology drug development, coupled with increased patient access and early diagnosis, has resulted in a massive increase in global spending on cancer treatments. Due to this, the global oncology market has been growing at an unprecedente...
BRIDGEWATER, N.J., April 10, 2023 (GLOBE NEWSWIRE) -- Hillstream BioPharma, Inc. (Nasdaq: HILS) ("Hillstream" or the "Company"), a biotechnology company developing a portfolio of therapeutic candidates targeting drug resistant and devastating cancers, announced pharmacokinetic (PK) data of HSB-12...
BRIDGEWATER, N.J., March 28, 2023 (GLOBE NEWSWIRE) -- Hillstream BioPharma, Inc. (Nasdaq: HILS) ("Hillstream" or the "Company"), a biotechnology company developing therapeutic candidates targeting drug resistant and devastating cancers using ferroptosis, and immuno-oncology targeted novel biologi...
Management will hold 1-on-1 meetings with institutional investors and analysts Company recently signed an exclusive option agreement with Applied Biomedical Science Institute (ABSI) to license technology for HER2 and HER3 BRIDGEWATER, N.J., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Hillst...
Gainers: Lucira Health ( LHDX ) +357% . ContraFect ( CFRX ) +75% . Moolec Science ( MLEC ) +29% . Werewolf ( HOWL ) +14% . The Pennant Group ( PNTG ) +16% . Losers: Genprex ( GNPX ) -17% . ETAO Internationl ( ET...
Hillstream BioPharma ( NASDAQ: HILS ) said it had regained compliance with the Nasdaq listing minimum bid price requirement for continued listing Hillstream was not in compliance with the minimum bid-price listing rule because its common stock failed to meet the closing bid price of...
Company Hosted its R&D Day to Discuss Product and Pipeline Goals Across 4 Pipeline Candidates and its Quatramer™ Tumor-Targeting Platform; Multiple inflection points over the next 12-18 Months Company’s Novel Emerging Anti-Cancer Mechanism, Ferroptosis, Addresses ...
Company’s Novel Emerging Anti-Cancer Mechanism, Ferroptosis, Addresses Potential Key Target Oncology Markets Projected to reach $11 Billion in 2028 Signs Exclusive Option Agreement with Applied Biomedical Science Institute to License Technology for HER2 and HER3 to be Develop...
Hillstream BioPharma ( NASDAQ: HILS ) is trading ~8.2% higher premarket after signing an agreement with Applied Biomedical Science Institute to license technology against drug resistant cancers including HER2-positive metastatic breast cancer, gastric cancer, lung cancer and...
News, Short Squeeze, Breakout and More Instantly...
Hillstream BioPharma Inc. Company Name:
HILS Stock Symbol:
NASDAQ Market:
Expects to launch and complete a Phase 1 trial in Q4 2023 Tharimmune to begin trading under new ticker, THAR, on Monday September 25, 2023 BRIDGEWATER, NJ / ACCESSWIRE / September 22, 2023 / Hillstream BioPharma Inc., (NASDAQ:HILS), a biotechnology company developing innovative therapeu...
JUPITER, Fla., Sept. 21, 2023 (GLOBE NEWSWIRE) -- via InvestorWire -- Dawson James Securities, Inc. (“Dawson”), a full-service investment bank focused on emerging growth companies, today announces its 8 th Annual Dawson James Small Cap Growth Conferen...
Anticipate completion of Phase 1 & Phase 2 clinical trials in chronic pruritis over the next approximately 12 months Seeking first approval in an orphan disease, PBC, for the treatment of moderate to severe chronic pruritis in which more than 70% of patients suffer from chronic prur...